Table 1.
Clinicopathological characteristics of the entire cohort and the NLR and SII subgroups.
| Mean (± SD) or counts (percentage of total) | |||||||
|---|---|---|---|---|---|---|---|
| Entire cohort | Low NLR | High NLR | P-value | Low SII | High SII | P-value | |
| Number | 291 | 141 | 150 | 129 | 162 | ||
| Age (years) | 66.13 ± 6.05 | 64.79 ± 5.95 | 67.4 ± 5.92 | 0.68 | 65.24 ± 6.11 | 66.90 ± 5.95 | 0.72 |
| BMI (kg/m2) | 24.35 ± 4.14 | 25.11 ± 4.74 | 23.63 ± 3.38 | 0.08 | 24.78 ± 4.96 | 23.98 ± 3.29 | 0.77 |
| tPSA (ng/ml) | 26.15 ± 33.77 | 19.42 ± 21.14 | 32.74 ± 41.88 | 0.04 | 18.66 ± 18.49 | 32.89 ± 42.23 | 0.004 |
| TPV (ml) | 36.62 ± 23.15 | 35.31 ± 24.66 | 37.73 ± 21.96 | 0.62 | 35.84 ± 24.83 | 37.25 ± 21.90 | 0.71 |
| GS (%) | 291 | 141 | 150 | 0.02 | 141 | 150 | 0.04 |
| ≤6 | 39 (13.4) | 21 (14.89) | 18 (12.0) | 24 (18.6) | 15 (9.3) | ||
| =7 | 129 (44.33) | 72 (51.1) | 57 (38.0) | 57 (44.2) | 72 (44.4) | ||
| ≥8 | 123 (42.27) | 48 (34.0) | 75 (50) | 48 (37.2) | 75 (46.3) | ||
| pT stage (%) | 291 | 141 | 150 | 0.006 | 129 | 162 | 0.007 |
| pT1 | 12 (4.12) | 9 (6.4) | 3 (2) | 4 (3.1) | 8 (4.9) | ||
| pT2 | 117 (40.21) | 66 (46.8) | 51 (34) | 65 (50.4) | 52 (32.1) | ||
| pT3 | 162 (55.67) | 66 (46.8) | 96 (64) | 60 (46.5) | 102 (63) | ||
BMI, body mass index; TPV, total prostate volume; GS, Gleason score; pT, pathological stage; NLR, neutrophil–lymphocyte ratio; SII, systemic immune-inflammation index.